Bionano to Participate in Maxim Group’s Covid-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing
The panel will include an interactive discussion moderated by Dr.
To access the panel discussion, please RSVP at https://m-vest.com/insights/blog/covid-19-virtual-conference.
| Panel Discussion Details: | |
| Panel Session Title: | Testing and Susceptibility – Clearing the Air |
| Date and Time: | |
About
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the impact of Saphyr on treatment or management of AML and ALL; our expectations regarding the future of cytogenetic analysis and Saphyr’s prominence; Saphyr’s readiness for widespread clinical adoption; and our efforts to execute on our commercial strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks that our preliminary financial information provided in this press release may not be as expected, as well as risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
Contacts
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
+1 (617) 430-7577
arr@lifesciadvisors.com
Media Contact:
+1 (508) 280-6592
kthomas@theruthgroup.com
Source: Bionano Genomics